Prostate cancer accounts for around one fifth of all male cancers, and most men with prostate cancer receive hormone therapy. This is often effective, however, in most cases progression occurs over time. This training course explores the latest clinical trials investigating new treatment options for patients with newly diagnosed mHSPC, including discussion of the ramifications of their findings for treatment in both the USA and Europe.

Immunotherapies are a relatively recent addition to the treatment armamentarium in GU oncology. This training course shares the latest information and expert opinion on the place of immunotherapy in the treatment of GU tumours, including guidance on the identification and management of immunotherapy-associated side effects.

EACCME Accreditation

COR2ED Checkpoint, made available on and organized by COR2ED, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at